Ignite Creation Date:
2024-05-05 @ 11:13 PM
Last Modification Date:
2024-10-26 @ 10:30 AM
Study NCT ID:
NCT01282593
Status:
COMPLETED
Last Update Posted:
2023-05-24
First Post:
2011-01-24
Brief Title:
Potential Role of CD9 and Implication of Motility Process in Pathogenesis of TELALM1-positive ALL Relapses LAL TELALM1 and CD9
Sponsor:
Rennes University Hospital
Organization:
Rennes University Hospital
Study Overview
Official Title:
Potential Role of CD9 and Implication of Motility Process in Pathogenesis of TELALM1-positive ALL Relapses LAL TELALM1 and CD9
Status:
COMPLETED
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LAL TELALM1
Brief Summary:
Down regulation of CD9 in TELAML1-positive ALL is addressed in motility assays to explore its role in B-ALL pathogenesis and its potential implication in relapses and prognosis
Detailed Description:
1 Assess of the impact of CD9 expression level on motility assays migration and adhesion We have initiated motility assays fibronectin adhesion experiments and CXCL12 chemoattracted migration tests with modified Boyden chamber technique using the CD9 positive TELAML1-positive cell line REH and the CD9 negative cell line RAJI wild or transfected with CD9 cDNA Data will be analyzed in combination with blocking antibodies and chemical antagonist according to the level of CD9 transcript and protein and of CXCR4 Protein quantifications will be performed by flow cytometry and Western Blot Interactions will be explored by confocal microscopy and biological pathways by immunoblot
Adhesion results will be validated on patient samples of B-ALL
2 Post-transcriptional regulation of CD9 in TELAML1-positive ALL To identify miRNAs that are potentially deregulated in TELAML1-positive acute lymphoblastic leukaemia and especially to screen for CD9 -targeted miRNAs we will use a TaqMan MicroRNA Arrays approach allowing the simultaneous measurement of about 760 human miRNA
Small RNA will be extracted from bone marrow samples of twenty childhood B-ALL to screen miRNAs which are differentially expressed between CD9-positive and CD9-negative ALL and further compared with miRNAs which were predicted to target CD9 in databases Validation of the selection will be performed by single Q-PCR for selected miRNAs using a novel cohort of ten bone marrow samples Transfection assays and luciferase assays will be further realized to confirm that the differential miRNAs really target and affect CD9 expression
Adhesion results will be validated on patient samples of B-ALL
2 Post-transcriptional regulation of CD9 in TELAML1-positive ALL To identify miRNAs that are potentially deregulated in TELAML1-positive acute lymphoblastic leukaemia and especially to screen for CD9 -targeted miRNAs we will use a TaqMan MicroRNA Arrays approach allowing the simultaneous measurement of about 760 human miRNA
Small RNA will be extracted from bone marrow samples of twenty childhood B-ALL to screen miRNAs which are differentially expressed between CD9-positive and CD9-negative ALL and further compared with miRNAs which were predicted to target CD9 in databases Validation of the selection will be performed by single Q-PCR for selected miRNAs using a novel cohort of ten bone marrow samples Transfection assays and luciferase assays will be further realized to confirm that the differential miRNAs really target and affect CD9 expression
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| B100651-40 | REGISTRY | AFSSAPS reference | None |
| 2010-A00622-37 | REGISTRY | None | None |